Olema Pharmaceuticals has entered into agreements to exchange shares of its common stock for pre-funded warrants with Bain Capital, Paradigm BioCapital, and BVF Partners, totaling approximately 6,070,000 shares, expected to close on January 13, 2025, increasing the total outstanding shares to about 68,333,065.